Illawarra Cancer Care Centre

Size: px
Start display at page:

Download "Illawarra Cancer Care Centre"

Transcription

1

2 The Audience Who? No apologies! Radiation Oncologists State of Mind Our business Our business is medical Our records are medical records Our information system is electronic medical record Primacy of our role Primary contact (process starts with what we serve up to rest) Legal responsibility Patient focus Experience of all units If you want to go electronic, doctors are the problem Ask IMPAC, Varian, Siemens,..

3 Begin at the End! What s my point? All data comes from a patient interaction SO you have mountains of data BUT the format is problematic EITHER.. Paper or Clinical Trial THUS useless or expensive WHAT IF You had a system where in the course of your normal workflow, you record your data, so that when you want to do an analysis the data s format is ready for analysis.

4 The Good News You have one. it s called IMPAC

5 The Bad News Implementing IMPAC within your department Process of Re-organisation Different look to paper Its not paper Paper is not that good Different workflow Different work paradigms 95% rule EFTPOD & data re-use No redundancy, only multiple viewing Rapid & frequent QA (education or retribution) Data Ownership (Users = Collectors & QA ors)

6 And the Oncologists said. I DON T BELIEVE YOU!

7 Demonstrate the possibilities How much data do you need to produce a paper? Let s look at a paper from a reputable centre Undertake a De-Constructive Content Analysis What is reported? What recorded dataset was it derived from? What choices were used in recording the data?

8 Demonstrate the possibilities

9 What was the utilised dataset? Diagnosis = Prostate (C61), NIDDM Histology = adenocarcinoma Gleason Score = 2-10 T stage = T1c, T2a, T2b, T2c, T3 N stage = N0 M stage = M0 PSA level Treatment intent = Curative Treatment_Protocol = MSKCC Prostate Dose Escalation Modality: Surgery = N, Radiotherapy = Primary, Hormone therapy = N/Y, Chemotherapy = N Radiation_Technique = 3DCRT Radiation_Dose = 64.8 Gy, 70.2 Gy, 75.6 Gy, and 81.0 Gy Plan_DVH_Volume (PTV) volume, length Plan_DVH_Structure (Rectum) volume, wall area, length, dose Acute Toxicity Score RTOG Acute Bowel Late Toxicity Score RTOG Late Bowel

10 How do you get this data? Discovered in clinic at first consultation Diagnosis = Prostate (C61), NIDDM Histology = adenocarcinoma Gleason Score = 2-10 T stage = T1c, T2a, T2b, T2c, T3 N stage = N0 M stage = M0 PSA level Where else is this found? Planning Request? Prescription? Discharge Summary? Letters?

11 How do you get this data? (2) Decided in clinic at first consultation Treatment intent = Curative Treatment_Protocol = MSKCC Prostate Dose Escalation Modality: Surgery = N, Radiotherapy = Primary, Hormone therapy = N/Y, Chemotherapy = N Radiation_Technique = 3DCRT Radiation_Dose = 64.8 Gy, 70.2 Gy, 75.6 Gy, and 81.0 Gy Radiation Fractionation = 2Gy/Fx Where else is this found?

12 How do you get this data? (3) Decided in Dosimetry at end of Planning Plan_DVH_Volume (PTV) volume, length Plan_DVH_Structure (Rectum) volume, wall area, length, dose BUT, can you enter this in IMPAC now?

13 No, so make a New Assessment! Plan_DVH_Volume (PTV) volume, length Plan_DVH_Structure (Rectum) volume, wall area, length, dose New IMPAC Assessment Name (GTV, CTV, PTV, Rectal Volume, Rectal Wall, ) Volume Length DVH1, DVH2, DVH3,.., DVH100 Enter data from each computer plan with marked volumes CLINICAL ASSESSMENTS infinitely expansible!

14 How do you get this data? (4) Decided in 'On Treatment Review' each week Acute Toxicity Assessment alternatives Descriptive Text 10 Nov Gy, mild-moderate bowel change, some tiredness, normal ECOG, no urinary problems. Continue. Acute Toxicity Score RTOG Acute Bowel 11/10/2006; Acute Bowel 1; Fatigue 1; ECOG 0; Acute Bladder 0; Treatment Status 0 Is there a difference in meaning? in format? [trial v clinical] in later analysis? can I turn the scores into text? Where else is this found?

15 How do you get this data? (5) Decided in Follow Up Clinic each visit Late Toxicity Score RTOG Late Bowel Same procedure as for Acute Toxicity!

16 Is this data any good? RETROSPECTIVE data or PROSPECTIVE data? VOLUME of data available? NZ data ( ) Stage 1-3 C61 per year Every weekly review has acute Bowel & Bladder toxicity measures How many observations? >6000! REAL data? ABSOLUTELY!

17 So the question is.. What else is needed to convince? That s an expensive piece of software and, by the way, it can run. Your machines Your clinics Your billing Your workflow Your clinical record Your medical record This functionality is NOT AVAILABLE in any other system that also runs machines

18 Can it improve my data? Only if you seek to own your data! QA the database Missing data Inconsistent data Immediately after entry Look for patients eligible for trial enrolment Immediately after data QA is successful! Look to see if you can do better Outcome Analysis Data managers can t do this.

19 Can it reduce my workload? Prescription Discharge Summary Departmental Report Paper Production

20 Some questions to think about? Is there any real difference between writing it on paper and entering it into the computer? Do I own my data? Does repeatedly entering the same data make it more certain? Are there enough computers to enter data anywhere that I sit? Does IMPAC have to match your procedures exactly?

21 The End! Thank you for the opportunity to relate my passion. I encourage you to think about the possibilities and to experiment with the system. If and when you want to go further, I can be contacted at alexisandrew@gmail.com.

22 Discharge Summary back

23 QA clerical back

24 QA medical back

25 Outcome Analysis back

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand

More information

New research in prostate brachytherapy

New research in prostate brachytherapy New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic

More information

New Technologies for the Radiotherapy of Prostate Cancer

New Technologies for the Radiotherapy of Prostate Cancer Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the

More information

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template

Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Public Comment Period for Proposed Radiation Oncology Survivorship Care Plan Template Purpose The aim of this ASTRO-sponsored Survivorship Care Plan (SCP) template is to formulate a standardized treatment

More information

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity

More information

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without

More information

Outline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT)

Outline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT) Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT) James Kavanaugh, MS DABR Department of Radiation Oncology Division of Medical Physics Outline Importance

More information

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia IMRT - the physician s eye-view Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia The goals of cancer therapy Local control Survival Functional status Quality of life Causes

More information

IMRT RTOG Definitive IMRT for Low Risk Prostate Cancer. All about dose and dose matters, probably Although hormones may matter

IMRT RTOG Definitive IMRT for Low Risk Prostate Cancer. All about dose and dose matters, probably Although hormones may matter Definitive for Low Risk Prostate Cancer Howard Sandler, MD, MS Bloom Family Chair in Cancer Therapeutics Cedar-Sinai Medical Center All about dose and dose matters, probably Although hormones may matter

More information

ONCOLOGY INFORMATION SYSTEMS

ONCOLOGY INFORMATION SYSTEMS ONCOLOGY INFORMATION SYSTEMS On colo gy Inf ormat io n sy st ems Outline OIS in general Benefits (POTENTIAL) Barriers (ACTUAL) Overcoming Difficulties (HOW TO MOVE) ARIA specifics On colo gy Inf ormat

More information

A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer

A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer Tony Kin Ming Lam Radiation Planner Dr Patricia Lindsay, Radiation Physicist Dr John Kim, Radiation Oncologist Dr Kim Ann Ung,

More information

ART for Cervical Cancer: Dosimetry and Technical Aspects

ART for Cervical Cancer: Dosimetry and Technical Aspects ART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray, Ph.D. Radiation Therapy Physics Princess Margaret Cancer Centre/Techna/Ontario Cancer Institute Professor Departments of Radiation

More information

Oral Communications. Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer

Oral Communications. Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer Oral Communications Elisa Zanardi UOC Clinica di Oncologia Medica Ospedale Policlinico San Martino Dipartimento di Medicina

More information

Prostate Cancer in comparison to Radiotherapy alone:

Prostate Cancer in comparison to Radiotherapy alone: Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +

More information

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery FILIPPO ALONGI MD Radiation Oncology & Radiosurgery Istituto Clinico

More information

BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital

BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital BRACHYTHERAPY FOR PROSTATE CANCER Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital PROSTATE BRACHYTHERAPY Why brachytherapy? How do we do it? What are the results? Questions?

More information

1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT

1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT Donald B. Fuller, M.D. 1, John Naitoh, M.D. 2, Mark Reilly, M.D. 3, Chad Lee, Ph.D 1. 1. CyberKnife Centers of San Diego, CA 2. Coast Urology La Jolla, CA 3. Sletten Cancer Center Great Falls, MT Typically,

More information

Leveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015

Leveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015 Leveraging Innovation to Design Future Clinical Trials Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A Perez Distinguished Professor of Radiation Oncology Outline National Clinical Trial Network

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA /2/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate

More information

Hypofractionation for Prostate Cancer: the Present Luca Incrocci, MD PhD

Hypofractionation for Prostate Cancer: the Present Luca Incrocci, MD PhD Hypofractionation for Prostate Cancer: the Present Luca Incrocci, MD PhD Professor of Genito-Urinary Radiotherapy Erasmus MC Cancer Institute Rotterdam, The Netherlands Themadag Prostaatcarcinoom 15 maart

More information

For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer

For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer Section For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer NCI/Local Protocol #: RTOG-0938/RTOG 0938 NCI Protocol Version

More information

The benefit of a preplanning procedure - view from oncologist. Dorota Kazberuk November, 2014 Otwock

The benefit of a preplanning procedure - view from oncologist. Dorota Kazberuk November, 2014 Otwock The benefit of a preplanning procedure - view from oncologist Dorota Kazberuk 21-22 November, 2014 Otwock Brachytherapy is supreme tool in prostate cancer management with a wide range of options in every

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

Big Data: How VHA Can Be Your Friend

Big Data: How VHA Can Be Your Friend Big Data: How VHA Can Be Your Friend Jatinder R Palta PhD Rishabh Kapoor MS Michael Hagan PhD, MD National Radiation Oncology Program(10P11H) Veterans Health Administration, USA Disclosure Vice President,

More information

Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation

Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation 2017 AAMD 42 nd Annual Meeting Neil C. Estabrook, MD 6 / 14 / 2017 7/5/2017 1 Conflicts of Interest None

More information

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University

More information

Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer

Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer Poster No.: RO-0049 Congress: RANZCR FRO 202 Type: Authors: Scientific Exhibit G. Govindarajulu, A.

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Number of targets 1. Number of OARs 2. Total number of plans 22. Analyzed OAR structures. Feature Min Max Mean Std

Number of targets 1. Number of OARs 2. Total number of plans 22. Analyzed OAR structures. Feature Min Max Mean Std VARIAN Model Analytics Model Name: Haris_PRO_Rez_Model_ Description FFF SingleArc Pläne (typ. PRO-Rezidiv) Dose prescriptions Gy (), 7 Gy (), 7 Gy (), Gy (), Gy () Model summary Number of targets Number

More information

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk

More information

Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques

Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques TROG 08.03 RAVES Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques Introduction Commissioning and quality assurance of planning systems and treatment delivery

More information

Specification of Tumor Dose. Prescription dose. Purpose

Specification of Tumor Dose. Prescription dose. Purpose Specification of Tumor Dose George Starkschall, Ph.D. Department of Radiation Physics U.T. M.D. Anderson Cancer Center Prescription dose What do we mean by a dose prescription of 63 Gy? Isocenter dose

More information

RPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy

RPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy RPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy Guidelines for Planning and Irradiating the RPC Liver Phantom. Revised Dec 2005 Credentialing for this protocol requires four steps:

More information

HDR vs. LDR Is One Better Than The Other?

HDR vs. LDR Is One Better Than The Other? HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs

More information

CyberKnife SBRT for Prostate Cancer

CyberKnife SBRT for Prostate Cancer CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes

More information

Margin Reduction in Prostate. Radiotherapy. Richard Oates, A/Prof Michal Schneider Monash Prof Tomas Kron Peter Mac Dr Michael Lim Joon Peter Mac

Margin Reduction in Prostate. Radiotherapy. Richard Oates, A/Prof Michal Schneider Monash Prof Tomas Kron Peter Mac Dr Michael Lim Joon Peter Mac Margin Reduction in Prostate Richard Oates, Radiotherapy Click to edit Master PhD Candidate subtitle style A/Prof Michal Schneider Monash Prof Tomas Kron Peter Mac Dr Michael Lim Joon Peter Mac Presentation

More information

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option

More information

Particle (proton) Therapy Randomized trials vs. Prospective registry. Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology

Particle (proton) Therapy Randomized trials vs. Prospective registry. Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Particle (proton) Therapy Randomized trials vs. Prospective registry Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Should we do randomized trials? Are randomized trials needed

More information

Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant

Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103 Implant Radiotherapy, Article ID 130652, 6 pages http://dx.doi.org/10.1155/2014/130652 Research Article Implant R100 Predicts Rectal Bleeding in Prostate Cancer Patients Treated with IG-IMRT to 45 Gy and Pd-103

More information

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom

17/07/2014. Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom My Biases Prostate Cancer Watchful Waiting New Treatments Andrew Williams Urologist and Urological Oncologist ADHB, CMDHB and 161 Gillies Ave, Epsom I am a member of the specialist group of the Prostate

More information

NICE BULLETIN Diagnosis & treatment of prostate cancer

NICE BULLETIN Diagnosis & treatment of prostate cancer Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In

More information

Feasibility of 4D IMRT Delivery for Hypofractionated High Dose Partial Prostate Treatments

Feasibility of 4D IMRT Delivery for Hypofractionated High Dose Partial Prostate Treatments Feasibility of 4D IMRT Delivery for Hypofractionated High Dose Partial Prostate Treatments R.A. Price Jr., Ph.D., J. Li, Ph.D., A. Pollack, M.D., Ph.D.*, L. Jin, Ph.D., E. Horwitz, M.D., M. Buyyounouski,

More information

IMRT for Prostate Cancer

IMRT for Prostate Cancer IMRT for Cancer All patients are simulated in the supine position. Reproducibility is achieved using a custom alpha cradle cast that extends from the mid-back to mid-thigh. The feet are positioned in a

More information

Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer

Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Notes: Information for Men Receiving Radiation and Hormone Treatments for Prostate Cancer Comments, Feedback? Contact Patient and Professional Education 519 685 8742 Email: lrcpeducation@lhsc.on.ca Reviewed

More information

Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia

Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast

More information

Radiation Therapy: From Fallacy to Science

Radiation Therapy: From Fallacy to Science 27 th Annual Management of Colon and Rectal Diseases 2.23.2019 Radiation Therapy: From Fallacy to Science Hadi Zahra, MD, DABR Radiation Oncologist CHI Health Henry Lynch Cancer Center Assistant Clinical

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

Treating Prostate Cancer

Treating Prostate Cancer Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and

More information

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer Proton Therapy for Low Risk Prostate Cancer Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments Andrew K. Lee, MD, MPH Associate Professor

More information

NRG ONCOLOGY (12/17/14)

NRG ONCOLOGY (12/17/14) NRG ONCOLOGY (12/17/14) RTOG 0232 A PHASE III STUDY COMPARING COMBINED EXTERNAL BEAM RADIATION AND TRANSPERINEAL INTERSTITIAL PERMANENT BRACHYTHERAPY WITH BRACHYTHERAPY ALONE FOR SELECTED PATIENTS WITH

More information

PACE Study. Hypofractionation 17/12/2014. Traditional Model of Fractionation 200 Response. What s the fraction sensitivity of prostate cancer?

PACE Study. Hypofractionation 17/12/2014. Traditional Model of Fractionation 200 Response. What s the fraction sensitivity of prostate cancer? 0 0 17/12/2014 2 Outline of today s talk PACE Study Background rationale for PACE? Dr Nicholas van As A bit about technology. What is PACE? How can I get involved? London: 1 December 2014 250 Hypofractionation

More information

What do we Know About Adaptive Radiotherapy? Lei Dong, Ph.D. Scripps Proton Therapy Center San Diego, California

What do we Know About Adaptive Radiotherapy? Lei Dong, Ph.D. Scripps Proton Therapy Center San Diego, California What do we Know About Adaptive Radiotherapy? Lei Dong, Ph.D. Scripps Proton Therapy Center San Diego, California AAMD Region II Meeting Houston, Texas September 13-14, 2012 Learning Objectives To gain

More information

Comparing Current Options in Radiation Therapy. Howard M. Sandler, MD Ronald H. Bloom Family Chair in Cancer Therapeutics Cedars-Sinai Medical Center

Comparing Current Options in Radiation Therapy. Howard M. Sandler, MD Ronald H. Bloom Family Chair in Cancer Therapeutics Cedars-Sinai Medical Center Comparing Current Options in Radiation Therapy Howard M. Sandler, MD Ronald H. Bloom Family Chair in Cancer Therapeutics Cedars-Sinai Medical Center Time Trends for Radiotherapy (and other treatments)

More information

IGRT Solution for the Living Patient and the Dynamic Treatment Problem

IGRT Solution for the Living Patient and the Dynamic Treatment Problem IGRT Solution for the Living Patient and the Dynamic Treatment Problem Lei Dong, Ph.D. Associate Professor Dept. of Radiation Physics University of Texas M. D. Anderson Cancer Center Houston, Texas Learning

More information

7/16/2009. Cost-benefit, QALYs and the Value of a Statistical Life

7/16/2009. Cost-benefit, QALYs and the Value of a Statistical Life 7/16/29 Cost-benefit, QALYs and the Value of a Statistical Life Alan McKenzie, Bristol The benefits of many developments in radiotherapy may be obvious for instance, replacing hand planning by computer

More information

Permanent Prostate Brachytherapy Post Procedure Evaluation

Permanent Prostate Brachytherapy Post Procedure Evaluation Permanent Prostate Brachytherapy Post Procedure Evaluation William S. Bice, Jr., Ph.D. UTHSCSA, San Antonio, Texas IMPS, San Antonio, Texas Texas Cancer Clinic, San Antonio, Texas Implant Evaluation for

More information

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff What Can Go Wrong in Radiation Treatment: Data from the RPC Geoffrey S. Ibbott, Ph.D. and RPC Staff Clinical NCI Trials CALGB 1768 Participating Institutions NCCTG ECOG COG ACOSOG SWOG QARC RPC ATC RTOG

More information

LDR Monotherapy vs. HDR Monotherapy

LDR Monotherapy vs. HDR Monotherapy Abstract No. 1234 LDR Monotherapy vs. HDR Monotherapy Is it time for LDR to retire? Gerard Morton 2 LDR Seed Brachytherapy First 2000 LDR patients from BCCA Low and Intermediate Risk LDR Implant Morris

More information

Vaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer. Scott Boulet BSc, RT(T)

Vaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer. Scott Boulet BSc, RT(T) Vaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer Scott Boulet BSc, RT(T) Outline Background Objectives Design Results Discussion Conclusion Acknowledgements Questions Background

More information

Rush University Medical Center RUMC XXXX

Rush University Medical Center RUMC XXXX Date: 03/10/2016 Rush University Medical Center RUMC XXXX A PROSPECTIVE EVALUATION OF MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (mpmri) GUIDED STEREOTACTIC BODY RADIATION TREATMENT FOR LOCALIZED PROSTATE

More information

Feasibility and initial dosimetric findings for a randomized trial using dose painted multi-parametric-mri defined targets in prostate cancer

Feasibility and initial dosimetric findings for a randomized trial using dose painted multi-parametric-mri defined targets in prostate cancer Feasibility and initial dosimetric findings for a randomized trial using dose painted multi-parametric-mri defined targets in prostate cancer Thoughts on the use of MRI in the treatment of prostate cancer

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

Radiotherapy Outcomes

Radiotherapy Outcomes in partnership with Outcomes Models with Machine Learning Sarah Gulliford PhD Division of Radiotherapy & Imaging sarahg@icr.ac.uk AAPM 31 st July 2017 Making the discoveries that defeat cancer Radiotherapy

More information

OPTIMIZATION OF COLLIMATOR PARAMETERS TO REDUCE RECTAL DOSE IN INTENSITY-MODULATED PROSTATE TREATMENT PLANNING

OPTIMIZATION OF COLLIMATOR PARAMETERS TO REDUCE RECTAL DOSE IN INTENSITY-MODULATED PROSTATE TREATMENT PLANNING Medical Dosimetry, Vol. 30, No. 4, pp. 205-212, 2005 Copyright 2005 American Association of Medical Dosimetrists Printed in the USA. All rights reserved 0958-3947/05/$ see front matter doi:10.1016/j.meddos.2005.06.002

More information

Provisional Accreditation

Provisional Accreditation August 14, 2017 Sudhakara Dandala Northern Arizona Tumor Institute 1100 Gail Gardner Way Prescott, AZ 86305 Dear Sudhakara Dandala: The American College of Radiation Oncology Accreditation Program conducted

More information

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat:

Clinical Management Guideline for Planning and Treatment. The process to be followed when a course of chemotherapy is required to treat: Clinical Management Guideline for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PROSTATE CANCER Patient information given at each stage following

More information

Basic Concepts in Image Based Brachytherapy (GEC-ESTRO Target Concept & Contouring)

Basic Concepts in Image Based Brachytherapy (GEC-ESTRO Target Concept & Contouring) Basic Concepts in Image Based Brachytherapy (GEC-ESTRO Target Concept & Contouring) Dr Umesh Mahantshetty, Professor, Radiation Oncology GYN & Urology Disease Management Group (DMG) Member Tata Memorial

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey

FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER Discover a test that can help you on your treatment journey Jim G. Oncotype DX GPS patient navigating prostate cancer since 2014 Not all prostate

More information

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research

More information

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus

More information

Helical Tomotherapy Experience. TomoTherapy Whole Brain Head & Neck Prostate Lung Summary. HI-ART TomoTherapy System. HI-ART TomoTherapy System

Helical Tomotherapy Experience. TomoTherapy Whole Brain Head & Neck Prostate Lung Summary. HI-ART TomoTherapy System. HI-ART TomoTherapy System The Challenges Associated with Differential Dose Delivery using IMRT Chester Ramsey, Ph.D. Director of Medical Physics Thompson Cancer Center Knoxville, Tennessee, U.S.A Collaborators Chester Ramsey, Ph.D.

More information

HDR Brachytherapy: Results and Future Studies in Monotherapy

HDR Brachytherapy: Results and Future Studies in Monotherapy HDR Brachytherapy: Results and Future Studies in Monotherapy Nikolaos Zamboglou and Nikolaos Tselis Strahlenklinik Klinikum Offenbach - Germany Prostate Brachytherapy UK & Ireland Conference 2013 Comparison

More information

Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) Quality Assurance Guidelines

Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) Quality Assurance Guidelines Prostate Brachytherapy QA Page 1 of 1 Transperineal Interstitial Permanent Prostate Brachytherapy (TIPPB) Quality Assurance Guidelines I. Purpose Table of Contents II. III. IV. Background Credentialing

More information

Diagnosis & Interventions

Diagnosis & Interventions Diagnosis & Interventions For doctors, the D&I screen is a quick visual summary of the patient's case, it is a very concise and easy to understand clinical history. The view is built from the entries placed

More information

La Pianificazione e I Volumi di Trattamento

La Pianificazione e I Volumi di Trattamento TRATTAMENTI INTEGRATI NEL CARCINOMA DELLA VULVA La Pianificazione e I Volumi di Trattamento PAOLO MUTO Direttore UOC Radioterapia ISTITUTO NAZIONALE TUMORI IRCCS Fondazione Pascale di Napoli Minimize collateral

More information

Oncology 101. Cancer Basics

Oncology 101. Cancer Basics Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases

More information

Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for

Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Inoperable Stage II-IIIB NSCLC 1 Co-Chairs Study Chair: Zhongxing

More information

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer

Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer Bowel Cancer in England and Wales A summary report about the management and outcomes of people with bowel cancer Based on findings from the National Bowel Cancer Audit Background How are patients diagnosed?

More information

Quality management for Breast Brachytherapy.

Quality management for Breast Brachytherapy. Quality management for Breast Brachytherapy. DORIN TODOR, Ph.D. Medical College of Virginia Campus Department of Radiation Oncology New England AAPM Chapter 2012 Summer Meeting, Providence, RI Quality

More information

Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?

Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure

More information

RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER

RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER RADIOTHERAPY IN THE MANAGEMENT OF CANCERS OF THE URINARY BLADDER INTRODUCTION Incidence: Mortality: 20/100000/year (Europe) 8-9/100000/year Worldwide fourth most common cancer in men Incidence: 31.1 mortality:

More information

Statistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer

Statistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer The African Review of Physics (2013) 8:0063 477 Statistical Analysis and Volumetric Dose for Organ at Risk of Prostate Cancer F. Assaoui¹,*, A. Bazine² and T. Kebdani³ ¹ Medical Physics Unit, Radiotherapy

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

Rectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers

Rectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers Rectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers 2015 MAC-AAPM Annual Meeting, Baltimore, MD Heeteak Chung,

More information

Proton therapy for prostate cancer

Proton therapy for prostate cancer Proton therapy for prostate cancer Shafak Aluwini Radiation oncologist UMCG Protons versus photons Superior beam properties 200 180 Advantage of protons 160 Photons 140 120 100 Spread out Bragg Peak 80

More information

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE)

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE) ESTRO Teaching Course on Image-guided radiotherapy & chemotherapy in gynaecological cancer - With a special focus on adaptive brachytherapy Prague, Czech Republic 22-26 October 2016 Course Directors: Richard

More information

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy The Physical and Biological Basis of By 1899 X rays were being used for cancer therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer

Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital

More information

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE)

Course Directors: Teaching Staff: Guest Lecturers: Local Organiser: ESTRO coordinator: Melissa Vanderijst, project manager (BE) ESTRO Teaching Course on Image-guided radiotherapy & chemotherapy in gynaecological cancer - With a special focus on adaptive brachytherapy Prague, Czech Republic 22-26 October 2017 Course Directors: Richard

More information

The British Journal of Radiology, 84 (2011),

The British Journal of Radiology, 84 (2011), The British Journal of Radiology, 84 (2011), 813 818 Assessing the daily consistency of bladder filling using an ultrasonic Bladderscan device in men receiving radical conformal radiotherapy for prostate

More information

RADIOTHERAPY DEPARTMENT

RADIOTHERAPY DEPARTMENT EXPERIENCES OF CLINICAL AUDIT IN A FINNISH RADIOTHERAPY DEPARTMENT Simo Hyödynmaa and Tuija Wigren Department of Radiation Therapy, Tampere University Hospital, Tampere, FINLAND PIRKANMAA HOSPITAL DISTRICT

More information

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC MRI Based treatment planning for with focus on prostate cancer Xinglei Shen, MD Department of Radiation Oncology KUMC Overview How magnetic resonance imaging works (very simple version) Indications for

More information

University of California, Los Angeles, Los Angeles, CA, 2 FROS Radiation Oncology and CyberKnife Center, Flushing, NY, 3

University of California, Los Angeles, Los Angeles, CA, 2 FROS Radiation Oncology and CyberKnife Center, Flushing, NY, 3 Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study A. U. Kishan 1, A. Katz 2, C. A. Mantz 3, F. I.

More information

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA /13/17 Eileen Tonner, MS NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #10: NCRA 2017-063 6/13/17 Eileen Tonner, MS Study Progress as of 6/13 Number of patients submitted as eligible: 2449 Number

More information

Faster Cancer Treatment Indicators: Use cases

Faster Cancer Treatment Indicators: Use cases Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:

More information

Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT

Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures

More information

PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:

PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital: May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx

More information